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Adenovirus-mediated /3-galactosidase gene delivery to the liver
leads to protein deposition in kidney glomeruli
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Adenovirus-mediated fi-galactosidase gene delivery to the liver leads to
protein deposition in kidney glomeruli. The many cell types of the kidney,
precisely arranged, allow this organ to perform its complex physiologic
functions. However, this architectural complexity makes gene transfer into
the kidney difficult. One approach to delivering a therapeutic protein to
the kidney is to transfer a gene to a non-renal tissue. Release of the
protein into the circulation might then result in deposition in the kidney,
if the protein has the appropriate molecular properties. In this study, we
found that parenterally administered replication deficient adenovirus
carrying the f3-galactosidase gene resulted in intense j3-galactosidase gene
expression in hepatocytes. As a result of immune attack on transduced
hepatocytes, f3-galactosidase protein from these cells is released into the
circulation, transported, and deposited almost exclusively in kidney gb-
meruli. Intense /3-galactosidase activity was noted in both kidneys with a
peak at two weeks following viral administration, concurrent with loss of
/3-galactosidase positive hepatocytes. Consistent with our hypothesis of
protein transfer, no /3-galactosidase mRNA was detected in glomeruli.
Moreover, systemically administered protein generated similar glomerular
/3-galactosidase activity. Finally, co-administration of murine CTLA4 Ig,
an immunomodulator of T cell activation, with the adenovirus protected
infected hepatocytes and markedly diminished glomerular /3-galactosidase
activity. Collectively, these findings suggest that a therapeutic protein can
be 'targeted" to the renal glomerulus, utilizing the liver as a gene transfer
organ.
The glomerulus, as a key structural unit within the kidney, is the
target of many renal diseases some of which lead to renal failure.
Knowledge of the molecular pathogenesis involved in glomerular
injury coupled to recent technological advances in gene delivery
make gene therapy for glomerular diseases an attractive proposi-
tion. As a critical first step, attempts at in vivo gene transfer into
the kidney have been made. However, gene transfer to the
glomerulus has been proven difficult (discussed below). An alter-
native strategy for treating glomerular disease would be to express
a therapeutic gene in another organ and use this organ as a depot
source for the gene product and to target the glomerulus. It is
conceivable that the size, charge and serum protein binding of
such a circulating molecule may allow it to selectively deposit into
different glomerular compartments.
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During the course of our previous studies on adenoviral gene
delivery to the kidney, we noted that virus entering the systemic
circulation invariably spreads to the liver, leading to hepatic
infection at high efficiency, a fact well known in the field. We
asked whether the liver could serve as a source of protein for
targeting to the kidney. A simple model system was to utilize
intravenously administered adenovirus carrying the /3-galactosi-
dase gene. Gene expression was expected to last for several weeks,
due to an immune response that destroys cells infected by the
virus [1—31. In the case of the liver, a hepatitis occurs. As a
consequence, it would not be unreasonable for /3-galactosidase
protein to be released into the systemic circulation. Interestingly,
the kidney glomerulus was found to be the major site of /3-
galactosidase activity with peak expression occurring at two
weeks, concurrent with loss of /3-galactosidase activity in the liver.
METHODS
In vivo adenovirus gene transfer
AdCMV/3-gal, a replication deficient adenovirus carrying the
/3-galactosidase gene under control of the immediate early cyto-
megalovirus (CMV) promoter-enhancer was a kind gift from Dr.
R. Crystal. n1sAdCMV/3-gal was identical to a AdCMV/3-gal but
with an SV4O T antigen nuclear localization signal added to theE.
coli /3-galactosidase gene (gift from Dr. C.B. Newgard) [4, 5].
AdCre is a replication deficient adenovirus harboring the Cre
recombinase of bacteriophage P1 under control of same CMV
promoter-enhancer element (generous gift from Dr. F.L. Gra-
ham) [6]. All three vectors are based on human adenovirus type 5
with El genes deleted from the genome. Therefore, they replicate
only in 293 cells, which supply E1A and E1B proteins in trans.
High titer stocks of recombinant adenovirus were prepared and
titered as described [7]. On the day prior to viral administration,
rats were injected intramuscularly (i.m.) with dexamethasone 130
j.g/kg and diphenhydramine 5 mg/kg (both from Elkins-Sinn,
Cherry Hill, NJ, USA). These medications were repeated at the
same dosage two hours prior to viral infusion. The rats (Wistar,
male, body wt range 200 to 300 g, Charles River Laboratories,
Wilmington, MA, USA) were infused via the tail vein with 8 ><
1011 viral particles (8 x i0 pfu) in 0.3 ml of PBS, immediately
following injection of 10 to 15 j.g epinephrine i.m. Intra-arterial
infusion into the rat kidney was conducted as described previously
[7], except that the above pre-treatments were utilized. All rats
receiving recombinant viruses survived to sacrifice.
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Histological analyses
f3-galactosidase histochemistiy. -galactosidase activity in tissue
was detected as described [7]. Briefly 2 to 4 mm thick tissue slices
were fixed in 4% paraformaldehyde/PBS at 4°C for two hours. For
gross staining, fixed tissue slices were washed in cold PBS for two
hours with three changes and incubated at 4°C for 24 hours with
a /3-galactosidase substrate cocktail. For histological staining,
fixed tissue blocks were incubated with 30% sucrose/PBS solution
at 4°C overnight and frozen with OCT compound (Miles, Fldhart,
IN, USA) in liquid nitrogen. Frozen sections were prepared,
incubated with the above substrate at 4°C overnight, and then
lightly counterstained with hematoxylin.
in situ hybridization. Fresh tissue slices were immediately snap-
frozen with OCT compound in liquid nitrogen. Dried frozen
sections (8 1km) were fixed with 3% paraformaldehyde at room
temperature for 30 minutes. The hybridization procedure using
digoxigenin-labeled cRNA probe was carried out as described [81.
Briefly, the fixed sections were incubated with 0.2 N HCI at room
temperature for eight minutes to inhibit endogenous alkaline
phosphatase and then with 0.1 M anhydride triethanolamine, pH
8.0 at room temperature for 15 minutes. The sections were
hybridized with the anti-sense digoxigenin-labeled cRNA probe
from a 1.12 kb SacI-ClaI fragment of the /3-galactosidase eDNA
(1:500 dilution from the original volume of 40 1.d) at 53°C
overnight in a humid chamber, followed by RNase digestion and
several stringent washes. To develop the hybridization signal, the
sections were incubated with sheep anti-digoxigenin antibody
conjugated with alkaline phosphatase (Boehringer Mannheim,
Indianapolis, IN, USA) for one hour at room temperature and
reacted with NBT/BCIP substrate solution (Boehringer Mann-
heim) at 4°C overnight. The sections were ready for microscopic
observation following mounting in aqueous medium.
Histopatho1oy. Frozen sections were stained with hematoxylin
and cosin. For certain experiments, paraffin sections were pre-
pared and PAS staining was performed to evaluate glomerular
injury. Random sections were examined in a blinded fashion.
Serum transaminase assay
Three rats were bled through the tail vein before and one and
two weeks after the intravenous (i.v.) administration of nlsAd-
CMVJ3-gal. Serum alanine aminotransferase was assayed with a
Boehringer Mannheim/Hitachi 717 Analyser and standard re-
agents used in a clinical chemical laboratory.
it?. coil fI-galactosidasc infusion
E. coil -galactosidase protein (E C3.2.1.23) was purchased
from Sigma (St. Louis, MO, USA). Two milligrams or 5 mg in 0.7
ml of PBS was slowly infused into the tail vein of 240 g Wistar rats
(Charles River Laboratories). Animals were sacrificed at 4.5 and
22 hours after p-galactosidase infusion. Various organs were
harvested for -galactosidase histochemical analysis.
CTLA4Ig production and administration
Production and purification of CTLA4Ig from the non-adher-
ent cell line NS-1 stably transfected with a murine CTLA4Ig gene
construct were conducted as described [9]. Briefly, the high
expression clone was cultured in serum-free medium for two
weeks. The culture supernatant was filtered (0.2 jim) and passed
through a protein A-Sepharose column (Pharmacia) after Tris-
HCI, pH 8.0, was added to a final concentration of 50 mrvi. Fluted
fractions were immediately buffered to a pH of 7.4 by addition of
0.1 volume of 1 M Tris-HC1, pH 8.0. Fractions with the greatest
absorbency at 280 nm were pooled and dialyzed against PBS
overnight at 4°C. To evaluate mCTLA4Ig function, Con A activity
of spleen cells was evaluated as described [9]. B6AF1 spleen cells
were incubated with mCTLA4Ig or control lgG2a mAb for one
hour in the presence of Con A and then 3 >< io spleen cells were
cultured in flat bottom 96-well microtiter plates for 48 hours. One
jsCi/well [3H] thymidine (Dupont NEN) was added during the last
six hours of culture and [3H] thymidine incorporation was mea-
sured utilizing a liquid scintillation counter.
Two milligrams of mCTLA4Ig was administered intraperitone-
ally (i.p.) into rats with body wt of 130 g 4.5 hours prior to infusion
of nlsAdCMVp-gal through the tail vein. Rats were sacrificed two
weeks later and /3-galactosidase activity was evaluated in various
organs. Liver injury was also assessed.
RESULTS
Glomerular 13-gal activity occurs following adenovirus-mediated
gene transfer
We have recently reported on successful adenovirus-mediated
gene transfer into normal and cystic rat kidneys using a cold
incubation protocol with and without vasodilators [7]. Transgene
expression in the virus-infused kidney was present primarily in
vasculature and in some interstitial elements. Importantly, only
very occasional glomerular cells were transduced. The right
kidney (uninfused) showed no gene expression three days after
gene transfer. In the liver, 70 to 80% of hepatocytes were
transduced, presumably from virus that escaped into the systemic
circulation following unclamping of the renal vein (data not
shown). In the spleen, a few white pulp cells were positive (data
not shown).
During the course of our studies to evaluate the duration of
transgene expression in the kidney, we sacrificed animals at one
week (3 rats) and two weeks (3 rats) following infusion of
nlsAdCMV/3-gal into the left kidney through the renal artery.
Compared to the data obtained from the rats at two to threes days
post-viral infusion, /3-galactosidase activity in the vasculature in
the virus-infused left kidney diminished somewhat at one week
and was markedly reduced, although still detectable at two weeks
post-viral infusion. These results were expected, since a cytolytic T
cell response often destroys adenovirus transduced cells (Fig. 1).
Surprisingly, however, all the glomeruli in both kidneys showed
light to moderate /3-galactosidase staining at one week (data not
shown) and even more intense staining at the two weeks time
point (Fig. 1). This /3-galactosidase activity appeared to be
localized in the cytoplasmic compartment of mesangial cells, even
though the nlsAdCMV/3-gal contained a nuclear localization
sequence. The percentage of /3-gal positive hepatocytes dimin-
ished somewhat at one week and was further reduced to 20 to
30% at two weeks following virus infusion (Fig. 2). Al one week
and two weeks, obvious hepatic injury was noted: spotty and focal
necrosis, ballooning degeneration, acidophilic bodies and mono-
nuclear cell infiltration, indicating hepatitis. Transaminase assay
of three rats showed that serum alanine aminotransferase was
increased from 45.67 t 10.77 ji/liter (mean SD) before virus
infusion to 261.67 36.59 js/liter (P < 0.01) at one week after
virus administration and dropped to 153.00 35.93 ji/liter (P <
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Fig. 1. Adenovirus-mediated glomerular a-gal activity. 13-gal activity was present in glomeruli of both kidneys two weeks following adenovirus infusion
through left renal artery in the presence of papaverine (A, X5.5) or through the tail vein (B, X1.9). Note that the vasculature (vasa recta) in the left
kidney of panel A is due to the LacZ gene transfer. On the section, 13-gal staining was seen in the mesangium of the glomeruli (C, x25 and D, X 100).
Abbreviations are: 1, left kidney; r, right kidney.
0.05) one more week later. These results were consistent with
histopathologic changes noted above.
To ask whether the bilateral glomerular -galactosidase stain-
ing was specific for virus infused through the renal artery, we
infused n1sAdCMV13-gal virus into rats through the tail vein and
checked 13-galactosidase activity at various time intervals. At two
days following viral infusion (3 rats), no /3-galactosidase activity
was detected in the kidney. At one week (3 rats) post-viral
infusion, all the glomeruli of both kidneys showed light /3-
galactosidase staining (data not shown), which intensified mark-
edly by two weeks (5 rats) and three weeks (3 rats) (Fig. 1) and
then gradually diminished over a five week period (2 rats)
following viral administration (data not shown). PAS staining of
the kidney sections at two weeks after viral infusion revealed no
obvious injury to the glomerulus (data not shown). At all time
points, /3-galactosidase activity in the liver and spleen was similar
to that seen in the renal arterially infused rats.
In a separate experiment, 7 X io pfu of AdCre virus was
administered intravenously into four rats. Two of them were
sacrificed at one week and the rest at two weeks after viral
administration. /3-galactosidase assay showed no detectable 13-
galactosidase activity in the kidneys, liver and spleen at either of
these time points (data not shown). This data further confirmed
that /3-galactosidase activity in the liver and kidneys from the rats
receiving LacZ containing adenoviral vectors was due to trans-
genie product from the viral vector.
There is no detectable transgene expression in the glomeruli
What is the nature of the above glomerular /3-galactosidase
activity? It seemed unlikely that this staining was mediated by in
Situ transgene expression in the glomeruli since peak activity
occurred approximately two weeks following gene transfer, when
/3-galactosidase expression of the liver and the renal vasculature
was greatly diminished. We decided to assess transgene expres-
sion in the glomeruli by utilizing in situ hybridization. Frozen
sections of both kidneys and the liver from rats sacrificed two
weeks (2 weeks liver or 2 weeks kidney) after viral infusion were
hybridized with digoxigenin-labeled transcripts derived from a
fragment of the [3-galactosidase eDNA. The liver and the kidneys
of a polyeystic kidney disease rat two days after gene transfer
mediated by the left renal artery served as positive controls [71.In
the two weeks liver, a few hepatocytes had /3-galactosidase mRNA
signal (data not shown), whereas no signal was detected in the
glomeruli, even though /3-galactosidase activity was manifest at
peak levels (Fig. 3).
'.• ...%•
"1. ,• : '•4 -' :'
-wet
1
•4-. .c.••
.M, _;S1. •
-
•
--'-S
•.-
•
•. -•
' .•, .-:
• . 4'-;
- 4'
Zhu et al: /3-galactosidase gene delivety 995
Fig. 2. 13-gal expression and inflammatory responce in the liver after viral infusion. In the liver from a rat sacrificed two days following viral infusion,
more than 80% of hepatocytes expressed /3-gal (A, x25) and no obvious pathological changes of hepatitis was noted (B, X25). Two weeks after viral
infusion, only 10 to 20% of hepatocytes were positive for p-gal (C, X25) and obvious patholoical changes of hepatitis including ballooning degeneration,
spotty necrosis (open bodied arrow) and acidophilic bodies (solid arrows) were noted (D, X25).
Infused -galactosidase protein deposits in the glomeruli
Since there was no evidence of transgene expression in the
glomeruli, we hypothesized that the glomerular /3-galactosidase
activity was mediated by functional 13-galactosidase protein syn-
thesized elsewhere, presumably in the liver, released into the
bloodstream and then transported into glomeruli. If our hypoth-
esis was correct, systemically infused E. co/i /3-galactosidase
protein might generate similar glomerular /3-galactosidase stain-
ing. We therefore infused via the tail vein 2.0 mg (4 rats) or 5,0 mg
(4 rats) of /3-galactosidase protein, and assayed for /3-galaetosi-
dase activity 4.5 or 22 hours afterwards. Both kidneys from the
rats receiving 2.0 mg of /3-galactosidase showed light 13-galactosi-
dase staining in glomeruli 4.5 hours (2 rats) post-/3-galactosidase
infusion. /3-galactosidase staining was also present in the papilla
on gross specimen but not present either in interstitial or in
vascular elements (data not shown). The glomerular /3-galactosi-
dase activity disappeared 22 hours (2 rats) following /3-galactosi-
dase administration.
The kidneys from rats receiving 5.0 mg of f3-galactosidase
protein and sacrificed 4.5 hours (2 rats) later presented a moder-
ate /3-galactosidase in every single glomerulus. The medulla and
papilla exhibited substantial staining (Fig. 4). In addition to the
renal /3-galactosidase activity, the hepatic sinusoidal wall cell,
presumably the Kupifer cell, and the splenic red pulp sinusoidal
cells were also stained at light to moderate levels (data not
shown). Twenty-two hours (2 rats) after infusion, /3-galactosidase
staining sharply diminished in the glomeruli and completely
disappeared in renal medulla and papilla, in the liver and in the
spleen. Based on the above observations, we concluded that at
least some /3-galactosidase protein can survive in the circulation in
a stable form, still retain functional activity and then deposit in the
glomeruli. The amount of activity deposited was dose dependent
and the approximate half-life in the positive cells was less than one
day.
Protection of adenovirus transduced hepatocytes by co-
administration of mCTLA4Ig reduces glomerular 13-
galactosidase activity
To test our assumption that /3-galactosidase released from
hepatoeytes that were subject to cytolytic T cell attack was then
being transported by the bloodstream into the glomeruli, we
employed the following experimental maneuver. Recent data
utilizing the immunosuppressive agent CTLA4Ig, a molecule that
blocks T cell activation, was shown to give longer-lived expression
of adenovirus transduced gene expression in the liver [10J. As-
suming this maneuver would extrapolate to rats, it could he
expected that co-administration of CTLA4Ig with the adenovirus
would protect /3-galactosidase positive hepatocytes from immune
attack and thereby diminish glomerular /3-galactosidase activity.
To test this hypothesis, we administered 2 mg of mCTLA4Ig
H'.,
I
, -r--:
eg. ;.-
-4.
, .-. I - 4. ' p.-,
it ... -I
-ç
4.1_p a.
4. 4. 4.- -
- '. F II—,
: &
A -- .1*
996 Zhu et ci: /3-gaiactosidase gene deiiveiy
tocytes showed nuclear 3-galactosidase staining with an obvious
hepatitis pathology. The glomerular -galactosidase staining was
uniformly intense in all glomeruli of both kidneys. On the other
hand, 60 to 70% of hepatocytes in the liver from the rats treated
with mCTLA4Ig remained /3-galactosidase positive, even though
some hepatic (hepatitis) pathology was also evident. Importantly,
in the kidneys from these rats, glomerular /3-galactosidase staining
was very light, indicating considerably less /3-galactosidase protein
present in the glomeruli, in agreemerTt with our hypothesis above
(Fig. 5).
DISCUSSION
Fig. 3. In situ hybridization analysis showing no transgene expression in
the glomerulus. Kidney section from a rat kidney two weeks after viral
infusion was hybridized with LacZ anti-sense riboprohe. No mRNA was
detectable in the glomeruli (A, ><25). B and C (x25) are positive
(anti-sense riboprohe)and negative (sense riboprobe) controls, respec-
tively. Sections were from the kidneys of a rat model of a polycystic kidney
disease, into which adenovirus was administered through the renal artery.
intraperitoneally into three rats with body wt of 130 g 4.5 hours
prior to infusion of 7 X io pfu of n1sAdCMV/3-gal virus via the
tail vein. Another group of three rats was injected intraperitone-
ally with the same volume of PBS prior to infusion of the same
amount of nlsAdCMV3-gal virus. /3-galactosidase activity in the
kidneys and liver was assessed two weeks later. The severity of
hepatic injury was also documented at the same time. In the liver
from rats receiving no mCTLA4Ig, approximately 30% of hepa-
Our data in this study show that /3-galactosidase expressed in
the liver through in vivo adenovirus-mediated gene transfer can
deposit selectively in the glomeruli of kidneys. This is supported
by the following facts: lack of evidence of in situ glomerular
transgene expression, similar glomerular deposition of intrave-
nously infused E. coli /3-galactosidase protein, and reduction of
glomerular /3-galactosidase activity when mCTLA4Ig is co-admin-
istered with the adenovirus. Interestingly, this observation of
glomerular deposition of /3-galactosidase protein has escaped
other investigators who have studi4l expression and decay of
/3-galactosidase activity in the hepatocytes of infected through i.v.
administration of the virus, presumably because the kidney was
not assessed in these studies. The results were a surprise to us,
since they imply that the 13-galactosidase protein can remain
functionally stable in the circulation and deposit more or less
selectively in the kidney glomerulus. However, the phenomenon
of protein deposition in the glomerulus is well-known to neph-
rologists and has been studied extensively [11, 12]. Determinants
such as the size and charge of the molecule [13], ability of the
molecule to be phagocytosed/endocytosed by mesangial cells,
extent of protein binding in the circulation, all play critical roles in
determining the localization of the molecule in the glomerulus.
Cationic antigens tend to deposit in subepithelial space. If no
antibody is present, they are removed in several hours. Anionic
antigens [14, 15] or antigens with large size [16] have tendency to
form deposits in mesangium. Under normal conditions, plasma
flow enters the mesangium through fenetrated endothelium,
bringing with it large particles (200 A to 300 A) [17]. E. coli
/3-galactosidase has a size of 120 A x 120 A x 70 A [18] with a
molecular weight of 465 kDa. Its estimated pK is 5.17, indicating
that it is an anionic protein under normal physiologic pH. It is not
unreasonable to speculate that the large size and anionic property
of the molecule determines its mesangial deposition localization.
However, the possibility exists that a portion of the protein
molecule mediates its selective mesangial deposition.
The /3-galactosidase protein when expressed in hepatocytes via
gene transfer was localized to the nuclei. This was expected since
the /3-galactosidase gene had been engineered to encode part of
the nuclear localization signal of the 5V40 T antigen. Curiously,
the protein appeared to remain in the cytoplasmic compartment
of the mesangial cells. Perhaps the protein had been modified or
lost part of this nuclear localizing function, as it entered into the
glomerulus or during its transit in the bloodstream.
Multiple lines of evidence suggest that the kidney /3-galactosi-
dase activity was produced by the virally introduced /3-galactosi-
dase and not due to endogenous activity. First, the /3-galactosidase
assay/conditions (neutral pH and 4°C) used in this study selec-
tively inhibit endogenous /3-galactosidase activity because the
.
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Fig. 4. Infused E. coli 13-gal protein deposits in the glomeruli. A total of 5 mg of E. co/i /3-gal protein was infused into the rats through the tail vein
and several organs were harvested 4.5 hours later for X-gal staining. A) Gross /3-gal staining of both kidneys: /3-gal activity showed in most glomeruli,
medulla and papilla (x1.9). (B and C) /3-gal activity in the glomeruli (B, x25 and C, X100). (D) /3-gal activity in deep medulla (X25). Abbreviations
are: I, left kidney; r, right kidney; pc, pelvic cavity.
optimal condition for the endogenous /3-galactosidase is low pH
(-5.5) and 37°C [19] and for the E. co/i one, pH >7 in the
presence of MgH [20]. These conditions suppress activity of
endogenous galactosidase sufficiently so that no staining of renal
tubular epithelial cells, where the kidney enzyme is primarily
located, was demonstrated. Second, our f3-galactosidase assay
method did not show galactosidase activity in the liver, spleen or
kidneys from normal control rats and the rats receiving the control
adenovirus AdCre. Finally, f3-galactosidase activity was detected
only in the hepatic nuclei when nIsAdCMVp-gal was adminis-
tered. In contrast, endogenous /3-galactosidase is localized in the
lysosome.
The glomerulus is an attractive target for gene/protein transfer
because many types of both acute and chronic glomerulonephrit-
ides affect the kidney, sometimes leading to loss of renal function.
In terms of gene transfer, Tomita et a! [21] have utilized a Sendai
virus (HVJ)/liposome complex to deliver the SV4O large T antigen
eDNA. Approximately 15% of cells in some glomeruli (cell type
unclear) expressed the gene for several days. Recently, Fine and
colleagues [221 injected mesangial cells into the renal artery. The
cells were engineered ex vivo with a retroviral vector containing
the /3-galactosidase gene. With this method, approximately 50%
of glomeruli were transduced and expression lasted four to eight
weeks. More recently, Tryggvasen's group [23] has shown that
both in vivo and ex vivo perfusion of adenovirus over a period of
2 to 12 hours can result in glomerular f3-galactosidase expression.
Though the data look strikingly similar to ours, the fact that the
expression occurred even in an ex vivo renal perfusion setting
suggests that it was not due to /3-galactosidase protein deposition.
Very recently, the concept of transferring proteins into the
glomerulus via gene transfer to a non-renal organ has been
exploited in the elegant studies of Border and his colleagues [24].
They utilized the HVJ liposome technology to intramuscularly
administer the eDNA for the glycoprotcin decorin. This glycopro-
tein is known to bind TGF-/3 (all three types). In the anti-Thy 1
model of glomerulonephritis, these investigators have shown that
the decorin released from the muscle can target the glomerulus
and abrogate some of the profibrotic actions of TGF-13. The
advantages of using liver over muscle as a source of protein would
be that a larger number of cells can be transduced, thus leading to
higher concentrations of the protein. For this technology to be
useful, a secreted protein would be utilized, as was the case in the
Border study. Problems relating to the inflammatory/immune
response to adenoviral vectors in the liver need to he obviated
either by future generation adenoviral vectors or through appro-
priate immunomodulatory techniques.
At present, it is unclear whether the /3-galactosidase protein has
rather unique characteristics that make it particularly useful for
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Fig. 5. Effects of CTLA4Ig on 13-gal expression
in the hepatocytes and 13-gal activity in the
glomeruli. 2 mg of mCTLA4Ig was
administered (i.p.) into rats 4.5 hours prior to
viral infusion. Animal were sacrificed two weeks
later. (A) Gross X-gal staining of the livers: the
liver from a rat receiving mCTLA4Ig (right)
had more 13-gal expression than the one from a
rat receiving no CTLA4Ig (left) (X4.5). (B)
Gross X-gal staining of the kidneys: the kidney
of the same rat receiving mCTLA4Ig (right) has
less 13-gal activity than the one from the one
receiving no mCTLA4Ig (left) (X5.2). (C) X-
gal-stained liver section of panel A, left (><25).
(D) X-gal-stained liver section of panel A, right.
(E) X-gal-stained section panel B, left (><25).
(F) X-gal-stained section of panel B, right
(x25).
targeting into the mesangium and the mesangial cell. For exam-
ple, it would be important to define which parts of the -
galactosidase protein possess this ability. It would also he inter-
esting to ask whether a fusion molecule between these parts of
/3-galactosidase and other molecules would he able to deposit
appropriately in glomeruli. Certainly the size, charge, protein
binding in the bloodstream as well as other properties of the
hybrid protein(s) would be important in determining the localiza-
tion of the protein in the glomerulus. Moreover, it would also be
important that the protein not be immunogenic or else the
recipient's immune response might in fact lead to an immune
complex glomerulonephritis. No histologic evidence of this, how-
ever, was noted at least over the two to three week period utilized
in our studies.
It is possible that the findings in this study may find application
in the assessment of renal function and/or imaging. For example,
partly or wholly sclerosed glomeruli might not take up the
13-galactosidase protein, thus making this molecule a candidate for
the development of novel noninvasive renal imaging technologies
to assess glomerular function. For example, the 13-galactosidase
protein could be appropriately labeled and then imaged. In
animal experiments requiring precise counting of glomeruli, in-
jecting the animal intravenously with 13-galactosidase would allow
easy visualization of glomeruli after sacrifice.
It is also conceivable that in the variety of disease states in the
glomerulus, either nephritic or nephrotic, very different localiza-
tions of a protein would be obtained. It would he very important
to assess where a given therapeutic protein localizes in the context
of the disease model. In summary, the study presented here opens
the possibility of utilizing the liver as a gene transfer organ for
targeting proteins into the kidney glomerulus, since the liver is
transduced very efficiently by systematically administered adeno-
virus.
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